EPO Does Not Improve Outcomes in Neonatal Hypoxic-Ischemic Encephalopathy

THURSDAY, July 14, 2022 -- For newborns undergoing therapeutic hypothermia for hypoxic-ischemic encephalopathy, erythropoietin administration does not yield a lower risk for death or neurodevelopmental impairment than placebo, according to a study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news